บูคินซา
BRUKINSA
activeLast updated: 2026-07-29
Product & certifications 1
- FDA 1C15008/67(NC)drugคงอยู่
ตัวยาสำคัญ
- ZANUBRUTINIB80.0 milligramต่อ 1 capsule
- ประเภทควบคุม
- ยาควบคุมพิเศษ
- ข้อบ่งใช้
- Mantle cell lymphoma (MCL) Zanubrutinib is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Waldenström’s Macroglobulinemia (WM) Zanubrutinib is indicated for the treatment of adult patients with Waldenström’s macroglobulinemia (WM). Marginal Zone Lymphoma Zanubrutinib is indicated for the treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one-prior anti-CD20-based therapy. Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Zanubrutinib is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Follicular Lymphoma (FL) Zanubrutinib in combination with obinutuzumab is indicated for the treatment of adult patients with follicular lymphoma (FL) who have received at least 2 prior therapies.
- รหัส ATC
- L01EL03 (zanubrutinib)
ข้อมูลตามที่ขึ้นทะเบียนกับ อย. — ไม่ใช่คำแนะนำการใช้ยา ปรึกษาเภสัชกรหรือแพทย์ก่อนใช้เสมอ
- Category
- ยาสำเร็จรูป
- Trade name
- —
- Company / Manufacturer
- บริษัท บีวัน เมดิซีนส์ (ประเทศไทย) จำกัด
- Producer's other permits
- See all permits held by this company →
A matching registration number confirms the registration exists — it does not verify that the physical item you hold is genuine. Always compare the product and manufacturer names on the label.
Last updated: 2026-07-29 · Data aggregated from official government databases: NBTC · FDA · TISI · DBD · Dept. of Tourism · ACFSReport incorrect data